Earlier this month Almac’s diagnostics arm launched a new biomarker development service which, as VP of business development Michael Sloan told Outsourcing-pharma, is intended to cater for growing biopharmaceutical manufacturing sector demand.
Sloan explained that demand for pharmacodynamic biomarkers, as well as those for clinical trial enrichment, is increasing day by day as everyone from Big Pharma to biotech recognises their value in the drug development process.
He also suggested that, increasingly, such companies are adopting broader strategies involving commercial development of biomarkers for in clinic diagnostics purposes which, while a new market, is one in which he sees considerable growth potential.